The directed issue to Gainbridge Capital is now registered
Calmark Sweden AB (publ) announces today that the directed issue of 388,936 B shares to Gainbridge Capital now has been registered. The issue was carried out at a subscription price of SEK 5.40 per B share, raising approximately MSEK 2.1 before issuance costs and increasing the share capital by SEK 38,893.60.
Gainbridge Capital, which has introduced the fund “Gainbridge Novus Nordic”, is a wholly-owned subsidiary of Spotlight Group AB. Gainbridge Novus Nordic invests in value-generating ideas that are based on innovation and create growth. The fund is focused on direct investment by means of capital raises in innovative Nordic growth companies, which enable the companies to implement and accelerate their journeys of development and growth.
“We are very happy that Gainbridge Capital has taken note of Calmark’s potential and decided to make an investment,” says Anna Söderlund, CEO of Calmark. “We would like to welcome Gainbridge Capital among the owners, and we look forward to a long-term cooperation.”
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
For more information about Calmark Sweden AB, please contact:
Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se
www.calmark.se
Calmark Sweden AB is a medical technology company that develops and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark sells a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.
Tags: